Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

John Smither Insider Profile

4 Followers

John Smither, Director at NewAmsterdam Pharma Company, holds 8.76K shares in NewAmsterdam Pharma Company (Ticker: NAMS), holds 28.00K shares in MBX Biosciences, Inc. (Ticker: MBX), holds 91.40K shares in Genelux Corp. (Ticker: GNLX). Most recently, John Smither Sold ― shares of NewAmsterdam Pharma Company on Sep 09, 2026 for an estimated value of $40.51K.

John Smither's Trading History

NAMSNewAmsterdam Pharma Company		Sep 09, 2026DirectorInformative Sell40.51K$175.73K
MBXMBX Biosciences, Inc.		Aug 04, 2026Chief Financial OfficerUninformative Buy―$1.56M
GNLXGenelux Corp.		Jul 02, 2026DirectorInformative Sell34.80K$190.12K
ARQTArcutis Biotherapeutics		Feb 15, 2024CFOUninformative Buy―$4.90M
EFTReFFECTOR Therapeutics		Aug 27, 2021DirectorUninformative Buy―$482.84
SNNAQSienna Biopharmaceuticals		Jan 03, 2019CFOUninformative Buy――
KYTHKythera		Oct 02, 2015―Uninformative Sell―$0.00
AKAOQAchaogen		―――$0.00
AMTIApplied Molecular Transport		――――
PRNBPrincipia Biopharma		――――
See All Insider Trading from Today

You May Also Like

Meet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.

John Smither insider profile FAQ

What is the percentage of profitable transactions made by John Smither?
The percentage of profitable transactions made by John Smither is 70%.
What is the average return per transaction made by John Smither?
The average return per transaction made by John Smither is 12.80%.
What stocks does John Smither hold?
John Smither holds: NAMS, KYTH, SNNAQ, PRNB, ARQT, AMTI, EFTR, GNLX, MBX, AKAOQ stocks.
What was John Smither’s latest transaction?
John Smither’s latest transaction was an Informative Sell of $40.51K.
What was John Smither's most profitable transaction?
John Smither’s most profitable transaction was an Informative Sell of GNLX stock on September 14, 2023. The return on the trade was 88.90%.
What is John Smither's role in NewAmsterdam Pharma Company?
John Smither's role in NewAmsterdam Pharma Company is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.